Zydus Life Q1 Result: Net Profit Falls 36% YoY Despite 22% Revenue Growth; Margin Contracts

Zydus Lifesciences had mixed financial performance in the first quarter of financial year 2027 as strong revenue growth does not translate into higher profitability. The pharmaceutical company’s consolidated net profit declined nearly 36% year-on-year (YoY) to Rs 940 crore in Q1 FY27, compared with Rs 1,467 crore in the same quarter of the last financial year.

The sharp decline in profit came despite a huge increase in revenue. Consolidated revenue from operations rose 22% YoY to Rs 8,017 crore as compared to Rs 6,574 crore in Q1 FY26. These results underline the pressure on profitability as costs increased during the quarter.

EBITDA Declines 7.6%

Zydus Lifesciences also reported a lower performance at the operating level. EBITDA declined 7.6% YoY to Rs 1,930 crore, compared to Rs 2,089 crore in the year-ago period.

Also Read

Top 10 Wealthiest Family Businesses in India 2026: Hurun List

The reduction in EBITDA had a dramatic impact on the company’s operating margin. EBITDA margin fell to 24.1% in Q1 FY27 from 31.8% in Q1 FY26, and operating profitability fell dramatically.

Higher revenue and lower EBITDA suggest that rising costs were an important factor on the company’s bottom line in the first quarter. Reuters also found sharply higher costs offset strong sales in key markets and contributed to a drop in quarterly profit.

India Business Maintains Growth Momentum

Even under pressure on total profitability, Zydus continued to grow in so many parts of its business.

The company’s India branded formulations business was strong and continued to outperform market growth. Its North America formulations business also saw sequential momentum with volume growth and new products launching.

International markets business continued its growth trajectory, supported by demand in key markets. Zydus’ Consumer Wellness business also maintained its lead in many major brands in India.

Regulatory Update

Zydus Lifesciences also provided an update on its manufacturing operations. Its injectable manufacturing facility at Zydus Biotech Park received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification after a Good Manufacturing Practices surveillance inspection during April and May 2026.

The company reported organic capital expenditure of around Rs 585.2 crore in the quarter and net debt at about Rs 5,904 crore at end of June 30, 2026.

In general, Zydus Life’s Q1 FY27 is mixed - revenue growth is strong but costs are rising and EBITDA and net profit are getting worse. Investors will monitor future quarters for margin recovery and long-term growth in the domestic and international businesses.